Forte Biosciences, Inc.
NASDAQ:FBRXBiotechnology
+$0.30 today
- Market cap
- $1.58B
- Beta
- 2.87
- P/E (TTM)
- -42.1
- EPS (TTM)
- -$0.43
Volume 0.00M
Average 0.30M
FBRX Total Debt
Short-term and long-term borrowings combined.
Forte Biosciences, Inc.NASDAQ: FBRX
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt remains negative
Q1 FY2026 total debt was $0, compared with $0 a year earlier.
Context
- Total debt amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Total debt increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Total Debt vs competitors
How FBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
- Total debt amounts to 0.0% of total assets for FBRX, versus a peer median of 10.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $76.79M USD | -7.9% | -10.7% | 27.0% | |
| Mar 2026 | $75M USD | -5.0% | -2.7% | 20.2% | |
| Mar 2026 | $34.55M USD | -15.8% | -5.8% | 14.4% | |
| Mar 2026 | $16.56M USD | -9.4% | -11.5% | 10.6% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $14.34M USD | +147.6% | +24.7% | 63.2% |
| Mar 2026 | CHF 3.33M CHF | +55.7% | -9.1% | 3.8% | |
| Mar 2026 | $1.21M USD | -57.8% | -59.8% | 0.8% | |
| Mar 2026 | $646K USD | -52.4% | -32.6% | 1.3% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $404.99K USD | — | +0.0% | 4.5% |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding FBRX) | — | -8.6% | -9.1% | 10.6% | |
Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Forte Biosciences, Inc.
NASDAQ:FBRX
Intrinsic Alpha fair value
Locked
Current Price
$76.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.